RECURRENT FOLLICULAR LYMPHOMA
Clinical trials for RECURRENT FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo aims to outsmart Tough-to-Treat lymphoma
Disease control Recruiting nowThis study is testing whether combining two drugs, pirtobrutinib and mosunetuzumab, works better for people with follicular lymphoma that has returned or not responded to previous treatments. The goal is to see if this combination can kill more cancer cells and potentially reduce…
Matched conditions: RECURRENT FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New engineered immune cell therapy enters first human trials for aggressive blood cancers
Disease control Recruiting nowThis is an early-stage study testing a new type of personalized cell therapy called MC10029 for adults with B-cell blood cancers that have come back or stopped responding to standard treatments. Researchers will first find the safest dose and then see if the therapy can shrink tu…
Matched conditions: RECURRENT FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC
-
New hope for lymphoma patients who have run out of options
Disease control Recruiting nowThis study is testing whether a drug called loncastuximab tesirine can shrink tumors in adults with specific types of B-cell lymphoma that have come back or stopped responding to other treatments. The drug is designed to target cancer cells directly. Researchers will give the dru…
Matched conditions: RECURRENT FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
New pill aims to turn immune system against tough blood cancers
Disease control Recruiting nowThis early-stage study is testing a new oral medication called Q702 for patients with advanced blood cancers and rare immune cell disorders that have not responded to standard treatments. The main goals are to find the safest dose and see what side effects occur. Researchers hope…
Matched conditions: RECURRENT FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 12, 2026 13:52 UTC